Is galectin-3 a good method for the detection of malignancy in patients with thyroid nodules and a cytologic diagnosis of “follicular neoplasm”? A critical appraisal of the evidence
✍ Scribed by Alvaro Sanabria; André Lopes Carvalho; Victor Piana de Andrade; Juan Pablo Rodrigo; José Guilherme Vartanian; Alessandra Rinaldo; Mauro Kazuo Ikeda; Kenneth Owen Devaney; José Magrin; Fernando Augusto Soares; Alfio Ferlito; Luiz Paulo Kowalski
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 131 KB
- Volume
- 29
- Category
- Article
- ISSN
- 1043-3074
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background.
Thyroid nodules are the most common surgical disease of the thyroid. Fine‐needle aspiration biopsy (FNAB) is the most commonly employed tool for establishing a diagnosis. However, 15% to 25% of FNAB reports yield inconclusive results. Immunostaining of cytological smears from FNAB with galectin‐3 has been proposed as a tool for differentiating between benign and malignant nodules. We performed a systematic review to evaluate the utility of galectin‐3.
Methods.
Prospective studies of nodules with FNAB reports of “follicular neoplasm” and with a definitive diagnosis confirmed by histopathology were selected. Calculations of individual sensitivity, specificity, and positive and negative likelihood ratios were made.
Results.
The articles selected were those with the best methodological quality.
Conclusion.
Galectin‐3 could be a good tool to guide therapeutic decision in patients with thyroid nodules and FNAB results of follicular neoplasm, but available information has methodological flaws that precludes a definitive answer about galectin‐3 utility in the clinical setting. © 2007 Wiley Periodicals, Inc. Head Neck 2007